Most models of neoadjuvant chemotherapy (NACT) for breast cancer (BC) suffer from insufficient data and lack interpretability. Additionally, there is a notable absence of reports from China in this field. This study is also the first to integrate the Advanced Lung Cancer Inflammation Index (ALI) into such a model to evaluate its effectiveness. Data from 3,036 female BC patients receiving NACT at Heilongjiang Provincial Tumor Hospital (2008-2019, median follow-up 7.28 years) were analyzed. After screening, 2,909 patients were randomized into training and validation cohorts (7:3). Using eXtreme Gradient Boosting (XGBoost), Gradient Boosting Classifier (GBC), Support Vector Machine (SVM) models, and SHapley Additive exPlanations (SHAP), the best predicting pathological complete response (pCR) model was identified, and key features were interpreted. The Least Absolute Shrinkage and Selection Operator (LASSO) Cox algorithm, combined with XGBoost and Random Forest (RF) models, identified 9 overlapping prognostic features, enhancing the nomogram's predictive accuracy for overall survival (OS). Kaplan-Meier (KM) analysis revealed varying prognostic outcomes. The XGBoost model performed best in predicting pCR, with Area Under Curve (AUC) values of 0.88 and 0.72 in the training and validation sets, respectively. SHAP analysis indicated that ER, HER2 status, ALI, and albumin (Alb) level were the four most important features. The prognostic model was also validated by high AUC values in both training and test sets. KM analysis indicated that lower ALI, non-pCR, and triple-negative BC manifested as worse clinical outcomes. However, the adverse impact of ALI on the prognosis of this cohort was mainly reflected in the long-term recurrence outcomes and non-pCR groups. This study is the first to introduce ALI into the prediction model for BC completing NACT and develop a large-sample model based on XGBoost. Owing to the particularity of the indicators, training and validation were conducted on real clinical data.
Breast cancer heterogeneity complicates prognosis and treatment. Metabolic reprogramming, particularly lysine beta-hydroxybutyrylation (Kbhb) driven by ket
Intrahepatic cholangiocarcinoma (iCCA) represents a growing health concern due to its increasing incidence and poor prognosis, highlighting the urgent need for biomarkers and therapeutic targets. This study utilized BayesPrism deconvolution, Weighted Gene Co-expression Network Analysis (WGCNA), and Summary Mendelian Randomization (SMR), integrated with single-cell RNA sequencing (scRNA-seq) data, to analyze the tumor microenvironment. Seven distinct cell subpopulations, including Exhausted CD8 + T cells (Tex), were identified. Notably, scPagwas analysis revealed gene enrichment in UQCRH, HINT1, and AKR1C3, associated with Tex. BayesPrism analysis confirmed their increased presence in the tumor microenvironment, indicating a role in immune evasion. WGCNA identified 594 genes linked to these cells, with PNO1 and AKR1C5P emerging as potential disease-associated genes. These findings highlight the critical role of Tex in immune suppression and identify key genes for further investigation in iCCA progression and treatment strategies.
Osteosarcoma (OS) is the most prevalent secondary sarcoma associated with retinoblastoma (RB). However, the molecular mechanisms driving the interactions between these two diseases remain incompletely understood. This study aims to explore the transcriptomic commonalities and molecular pathways shared by RB and OS, and to identify biomarkers that predict OS prognosis effectively. RNA sequences and patient information for OS and RB were obtained from the University of California Santa Cruz (UCSC) Xena and Gene Expression Omnibus databases. When RB and OS were first identified, a common gene expression profile was discovered. Weighted Gene Co-expression Network Analysis (WGCNA) revealed co-expression networks associated with OS after immunotyping patients. To evaluate the genes shared by RB and OS, univariate and multivariate Cox regression analysis were then carried out. Three machine learning methods were used to pick key genes, and risk models were created and verified. Next, medications that target independent prognostic genes were found using the Cellminer database. The comparison of differential gene expression between OS and RB revealed 1216 genes, primarily linked to the activation and proliferation of immune cells. WGCNA identified 12 modules related to OS immunotyping, with the grey module showing a strong correlation with the immune-inflamed phenotype. This module intersected with differential genes from RB, producing 65 RB-associated OS Immune-inflamed Genes (ROIGs). Analysis identified 6 hub genes for model construction through univariate Cox regression and three machine learning techniques. A risk model based on these hub genes was established, demonstrating significant prognostic value for OS. Genes shared between OS and RB contribute to the progression of both cancers through multiple pathways. The ROIGs risk score model independently predicts the overall survival of OS patients. Additionally, this study highlights genes with potential as therapeutic targets or biomarkers for clinical use.